French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock ...

Alzheimer's patients have new hope with Kisunla and Zunveyl, which target the disease in unprecedented ways, while Dupixent ...